Skip to main content

AbbVie vs Eli Lilly: Revenue, Profit and Business Model

AbbVie had $61.2B of annual revenue in FY2025 and $4.2B of net income. Eli Lilly had $65.2B of annual revenue in FY2025 and $20.6B of net income.

Latest financial snapshot

AbbVie

Latest annual revenue
$61.2B (FY2025)
Net income
$4.2B
Net margin
6.9%
Revenue growth
+10.1% a year, FY2016–FY2025

Eli Lilly

Latest annual revenue
$65.2B (FY2025)
Net income
$20.6B
Net margin
31.7%
Revenue growth
+13.3% a year, FY2016–FY2025

Financial summary

AbbVie

AbbVie reported $61.160 billion of FY2025 net revenue and $4.226 billion of net income. Skyrizi and Rinvoq generated $25.866 billion combined, while Humira declined to $4.540 billion after U.S. biosimilar entry. The 2020 Allergan acquisition added neuroscience and aesthetics revenue, and the 2024 ImmunoGen and Cerevel acquisitions added oncology and neuroscience assets. AbbVie is a dominant biopharmaceutical company, sustaining a massive market valuation often exceeding $250 billion, heavily driven by its blockbuster immunology and aesthetics portfolios.

Eli Lilly

Revenue rose from $28.5 billion in 2022 to $45.0 billion in 2024 and $65.2 billion in 2025, while net income nearly doubled to $20.6 billion. Growth accelerated again in 2026: second-quarter revenue rose 48% to $23.0 billion, with Mounjaro at $9.94 billion (up 91%) and Zepbound at $4.93 billion. Lilly raised 2026 revenue guidance to $85-87 billion and non-GAAP EPS guidance to $35.50-36.50. Capital expenditures reached $7.8 billion in 2025 as Lilly expanded production capacity. Eli Lilly and Company is a pharmaceutical titan that has experienced massive growth, commanding a monumental market valuation frequently exceeding $700 billion.

Revenue and profit by year

AbbVie

AbbVie revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025$61.2B$4.2B6.9%+8.6%Source
FY2024$56.3B$4.3B7.6%+3.7%Source
FY2023$54.3B$4.9B9.0%-6.4%Source
FY2022$58.1B$11.8B20.4%+3.3%Source
FY2021$56.2B$11.5B20.5%+22.7%Source
FY2020$45.8B$4.6B10.1%+37.7%Source
FY2019$33.3B$7.9B23.7%+1.6%Source
FY2018$32.8B$5.7B17.4%+16.1%Source
FY2017$28.2B$5.3B18.8%+10.1%Source
FY2016$25.6B$6B23.2%—Source
Full AbbVie financials

Eli Lilly

Eli Lilly revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025$65.2B$20.6B31.7%+44.7%Source
FY2024$45B$10.6B23.5%+32.0%Source
FY2023$34.1B$5.2B15.4%+19.6%Source
FY2022$28.5B$6.2B21.9%+0.8%Source
FY2021$28.3B$5.6B19.7%+15.4%Source
FY2020$24.5B$6.2B25.2%+9.9%Source
FY2019$22.3B$8.3B37.3%+3.8%Source
FY2018$21.5B$3.2B15.0%+7.6%Source
FY2017$20B-$204.1M-1.0%-5.9%Source
FY2016$21.2B———Source
Full Eli Lilly financials

Where the revenue comes from

AbbVie

  • Immunology Portfolio49.7%

    FY2025 revenue was $30.406 billion, led by Skyrizi, Rinvoq, and Humira.

  • Neuroscience Portfolio17.6%

    FY2025 revenue was $10.767 billion, including Vraylar, Botox Therapeutic, Ubrelvy, and Qulipta.

  • Oncology Portfolio10.9%

    FY2025 revenue was $6.655 billion, including Imbruvica, Venclexta, and Elahere.

  • Aesthetics Portfolio7.9%

    FY2025 revenue was $4.860 billion, including Botox Cosmetic and Juvederm.

  • Other Products and Revenue13.9%

    The remaining FY2025 revenue came from eye care, other specialty products, and other revenue.

Eli Lilly

  • Branded Prescription MedicinesPrimary

    Sales of patent-protected medicines through wholesalers, pharmacies, health systems, and international channels.

  • Collaborations and Licensing

    Supporting

    Milestones, royalties, and collaboration economics connected to research, development, and commercialization partnerships.

Business model and strategy

AbbVie

How it makes money

AbbVie Inc. is a global biopharmaceutical research and development company that discovers, manufactures, and markets advanced medicines across immunology, oncology, neuroscience, and aesthetic medicine. Formed in 2013 as a spin-off from Abbott Laboratories, AbbVie built its initial commercial empire around Humira (adalimumab)—historically the world's best-selling biologic medicine.

Growth strategy

AbbVie is expanding approved uses and commercial reach for Skyrizi and Rinvoq while investing in oncology and neuroscience. ImmunoGen added Elahere and antibody-drug conjugate programs, Cerevel added clinical-stage neuroscience programs, and Allergan added Botox, Vraylar, migraine products, eye care, and aesthetics.

Competitive advantage

AbbVie's durable competitive moat is built upon its world-class commercial execution in immunology, unmatched patent estate design, and the high-margin cash flow engine of the Allergan aesthetics portfolio.

AbbVie business model in full

Eli Lilly

How it makes money

Eli Lilly and Company is an innovation-driven global pharmaceutical titan that discovers, develops, manufactures, and commercializes human therapeutics across endocrinology, oncology, immunology, and neuroscience.

Growth strategy

Lilly's growth strategy has three parts: expand incretin supply and indications, add oral and next-generation obesity medicines, and diversify through oncology, immunology, neuroscience and genetic medicine. Foundayo (orforglipron) was approved by the FDA on April 1, 2026 and launched through LillyDirect, telehealth and U.S. retail pharmacies. Retatrutide, a GIP/GLP-1/glucagon triple agonist, is in Phase 3.

Competitive advantage

Eli Lilly's formidable economic moat is founded on its multi-decade dominance in peptide synthesis, patent-protected intellectual property, and extensive global sterile manufacturing infrastructure.

Eli Lilly business model in full

Questions about AbbVie vs Eli Lilly

Which company has higher revenue — AbbVie Inc. or Eli Lilly and Company?

AbbVie Inc. had $61.2B (FY2025), while Eli Lilly and Company had $65.2B (FY2025). By latest annual revenue, Eli Lilly and Company is the larger business, with AbbVie Inc. showing a smaller revenue base.

What is the market cap of AbbVie Inc. vs Eli Lilly and Company?

AbbVie Inc.'s market capitalisation stands at $465.8B, while Eli Lilly and Company's is $1.06T. Eli Lilly and Company carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to AbbVie Inc..

How does revenue per employee compare for AbbVie Inc. and Eli Lilly and Company?

AbbVie Inc. has $1.07M / employee in revenue per employee, while Eli Lilly and Company has $1.30M / employee. Headcounts may use different dates, so the ratio alone does not establish which business operates more efficiently.

How do AbbVie Inc. and Eli Lilly and Company make money?

AbbVie Inc. and Eli Lilly and Company generate revenue in fundamentally different ways. AbbVie Inc.: AbbVie Inc. is a global biopharmaceutical research and development company that discovers, manufactures, and markets advanced medicines across immunology, oncology, neuroscience, and aesthetic medicine. Eli Lilly and Company: Eli Lilly and Company is an innovation-driven global pharmaceutical titan that discovers, develops, manufactures, and commercializes human therapeutics across endocrinology, oncology, immunology, and neuroscience.

Which company is valued higher relative to revenue — AbbVie Inc. or Eli Lilly and Company?

On a price-to-sales (P/S) basis, AbbVie Inc. trades at 7.6x P/S and Eli Lilly and Company at 16.3x P/S. Eli Lilly and Company commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to AbbVie Inc.. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.

Is AbbVie Inc. bigger than Eli Lilly and Company?

By last reported revenue, Eli Lilly and Company ($65.2B (FY2025)) is the larger company compared to AbbVie Inc. ($61.2B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AbbVie vs Eli Lilly overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.